Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations

Схожие документы

• Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
  по: Riely, Gregory J., et al.
  Опубликовано: (2021)
• Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
  по: Vasconcelos, Pedro E.N.S., et al.
  Опубликовано: (2020)
• Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
  по: Lin L, et al.
  Опубликовано: (2020-09-01)
• Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
  по: Lin, Ling, et al.
  Опубликовано: (2020)
• Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity
  по: Xiuning Le, et al.
  Опубликовано: (2025-09-01)